News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

James Hoyes

Advertisement

Articles by James Hoyes

Maximize New Product Potential Through Early Commercial Planning

ByNick DeSanctis,Subbarao Jayanthi,James Hoyes
November 15th 2019

Five key areas biopharma manufacturers focus on to predict where the markets will be and determine how standards of care will evolve to effectively position new products.

Advertisement

Latest Updated Articles

  • Maximize New Product Potential Through Early Commercial Planning
    Maximize New Product Potential Through Early Commercial Planning

    Published: November 15th 2019 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics

2

FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma

3

Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform

4

The Situation We Faced: The Development and Commercialization of MariTide

5

DSCSA Is Not the Finish Line, It’s the Starting Gate

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us